Mohammed T. Abou-Saleh

PRESENT AND FUTURE TREATMENTS OF AD 323accumulation in Alzheimer’s disease transgenic mice. Neuron 2011;30: 665–7.96. Esiri MM. Is an effective immune intervention for Alzheimer’s diseasein prospect? Trends Pharmacol Sci 2001; 22: 2–3.97. Ingram DK. Vaccine development for Alzheimer’s disease: a shot ofgood news. Trends Neurosci 2001; 24: 305–37.98. Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-attenuates Alzheimer disease-like pathology in the PDAPP mouse.Nature 1999; 400: 173–7.99. Bard F, Cannon C, Barbour R et al. Peripherally administeredantibodies against amyloid peptide enter the central nervous systemand reduce pathology in a mouse model of Alzheimer disease.Nature Med 2000; 6(8): 16–19.100. Janus C, Pearson J, McLaurin J et al. A -peptide immunizationreduces behavioural impairment and plaques in a model ofAlzheimer’s disease. Nature 2000; 408: 979–82.101. Morgan D, Diamond DM, Gottschall PE et al. A -peptidevaccination prevents memory loss in a model of Alzheimer’sdisease. Nature 2000; 408: 982–85.102. Hyman BT, Smith C, Buldyrev I et al. Autoantibodies to amyloid-and Alzheimer’s disease. Ann Neurol 2001; 49: 808–10.